【Objective】Retrospective study on the clinical characteristics and the long-term clinical outcome of regulatory follow-up chronic HBV infection patients achieving HBsAg seroclearance after long-term nucleos（t）ideanalogues （NA）treatment.【Methods】127 chronic hepatitis B infection patients with HBsAg seroclearance after NA long-termtreatment were selected as the study subjects，23 patients loss of follow-up，and104patientswereenrolledinthestudy.Rou? tinelycollectedclinicaldataofthe104 patients with HBsAg seroclearance，including patient demographic data，family history，personal history，base line and follow-up at each time point of biochemical，virological，serologicalresponse data，liver and spleenimaging indexes and drug safety during the treatment.Primary end point：HBsAg seroclearance rate （semiquantitative method：HBsAgtiter<1.0COI；quantitative method：HBsAgtiter<0.05U/mL） .【Results】In these patients who achieved serum HBsAg negative，86.6%（89 cases）were male，37.7%（34）were HBeAg positive at baseline. When HBsAg seroclearance after 5.5（0.3-14.0）years follow-up，the mean age was 49.0（27.0～81.0）years，ALT normalization was 66.2%（48/68）and HBV DNA undetectable rate was 98.1%（102/104），HBeAg seroclearance rate was 85.3%（29/34），HBeAg/HBeAb seroconversion rate was 79.4%（27/34），HBsAg/HBsAb seroconversion rate 7.7%（8/104）. In the last follow-up，ALT normalization was 83.8%（57/68）and HBV DNA undetectable rate was 99.1% （103/104），HBeAg seroclearance rate was 88.2%（30/34），HBeAg/HBeAb seroconversion rate was 79.4%（27/34）， HBsAg seroclearance rate was 97.1%（101/104），HBsAg/HBsAb seroconversion rate 27.9%（29/104） . 3 cases in patients HBsAg turned positive again，but the level of lgHBsAg were very low，ranged from-0.3to0.7U/mL. 3 patient developed disease progression to livercirrhosisor livercancer，and no one patient died. 【Conclusion】 The long-term clinical prognosis of CHB patients with HBsAg seroclearance after long-term NA antiviral therapy was favourable.